
















Leu20-Asp339
Accession # P08887


Scientific Data

Detection of Recombinant Human IL-6R alpha by Western Blot. Western blot shows 25 ng of Recombinant Human IL-6R alpha (Catalog # 227-SR) and Recombinant Mouse IL-6R alpha (Catalog # 1830-SR). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human IL-6R alpha Monoclonal Antibody (Catalog # MAB227) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for IL-6R alpha at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.

Detection of IL-6R alpha in U937 Human Cell Line by Flow Cytometry. U937 human histiocytic lymphoma cell line was labeled with Human IL-6R alpha Monoclonal Antibody (Catalog # MAB227, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')2Secondary Antibody (Catalog # F0102B).

IL-6R alpha Enhancement of IL‑6-dependent Inhibition of Cell Proliferation and Neutralization by Human IL-6R alpha Antibody. Recombinant Human IL-6R alpha (Catalog # 227-SR) enhances Recombinant Human IL-6 (Catalog # 206-IL) inhibition of proliferation in the M1 mouse myeloid leukemia cell line in a dose-dependent manner (orange line). Enhancement of Recombinant Human IL-6 (30 ng/mL) activity elicited by Recombinant HumanIL-6R alpha (30 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL-6R alpha Monoclonal Antibody (Catalog # MAB227). The ND50 is typically 0.04-0.2 µg/mL.
Human IL-6R alpha Antibody Summary
Leu20-Asp339
Accession # P08887
Applications
Human IL-6R alpha Sandwich Immunoassay
Measured by its ability to neutralize IL-6R alpha-mediated enhancement of IL‑6-dependent Inhibition of cell proliferation in the M1 mouse myeloid leukemia cell line. The Neutralization Dose (ND50) is typically 0.04-0.2 µg/mL in the presence of 30 ng/mL Recombinant Human IL-6R alpha and 30 ng/mL Recombinant Human IL‑6.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.


Background: IL-6R alpha
The multi-functional factor interleukin 6 (IL-6) exerts its activities through binding to a high-affinity receptor complex consisting of two membrane glycoproteins: an 80 kDa component receptor that binds IL-6 with low affinity (IL-6 R alpha ) and a signal-transducing component of 130 kDa (gp130) that does not bind IL-6 by itself, but is required for high-affinity binding of IL-6 by the complex. Both components of the receptor complex, IL-6 R alpha and gp130 have been cloned, sequenced, and expressed (1-4).
A soluble form of the IL-6 R alpha has been found in the urine of healthy adult humans (5). This soluble receptor apparently arises from proteolytic cleavage of membrane-bound IL-6 R alpha and is about 50kDa in size. No naturally-occurring mRNA encoding a truncated form of the IL-6 R alpha has been reported. Soluble forms of human and murine IL-6 R alpha s have been constructed, however, by insertion of termination codons into the regions of the IL-6 R alpha cDNAs encoding the external portions of the receptors and prior to the transmembrane domains. These soluble receptors have been expressed in COS-7 and CHO cells and have been shown to bind to IL-6 in solution and to augment the activity of IL-6 as a result of the binding of the IL-6/IL-6 R alpha complex to membrane-bound gp130 (6, 7).
- Yamasaki et al. (1988) Science 241:825.
- Baumann et al. (1990) J. Biol. Chem. 265:19853.
- Hibi et al. (1990) Cell 63:1149.
- Schooltink et al. (1991) Eur. J. Biochem. 277:659.
- Novick et al. (1989) J. Exp. Med. 170:1409.
- Yasukawa et al. (1990) J. Biochem. 108:673.
- Saito et al. (1991) J. Immunology 147:168.


Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
参考图片
IL‑6 R alpha Enhancement of
IL‑6-dependent Inhibition of Cell Proliferation and Neutralization by Human
IL‑6 R alpha Antibody. Recombinant Human IL‑6 R alpha (Catalog #
227-SR) enhances Recombinant Human IL‑6 (Catalog # 206-IL) inhibition of proliferation in the M1 mouse myeloid leukemia cell line in a dose-dependent manner (orange line). Enhancement of Recombinant Human IL‑6 (30 ng/mL) activity elicited by Recombinant Human IL‑6 R alpha (30 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL‑6 R alpha Monoclonal Antibody (Catalog # MAB227). The ND50 is typically
0.04-0.2 µg/mL.
Detection of IL‑6 R alpha in U937 Human Cell Line by Flow Cytometry. U937 human histiocytic lymphoma cell line was labeled with Human IL‑6 R alpha Monoclonal Antibody (Catalog # MAB227, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG
F(ab')2 Secondary Antibody (Catalog # F0102B).